MicroPort Promotes Firehawk<sup>®</sup> in TCT 2014

Washington DC, US – 19 September, 2014 - Shanghai MicroPort Medical (Group) Co ("MicroPort") attended the 26th Transcatheter Cardiovascular Therapeutics (TCT) held from 13 September to 17 September in Washington DC, to further promote its third-generation Drug Eluting Stent ("DES") Firehawk® Rapamycin Target Eluting Coronary Stent ("Firehawk®").
 
During TCT, the world's largest educational meeting specializing in interventional cardiovascular medicine, MicroPort rebroadcasted two operations in which Firehawk® was used to treat left main bifurcation lesions, a cardiovascular disease. Meanwhile, Beijing-based Fuwai Hospital's Vice President Yuejin Yang and Professor Shubin Qiao were invited to introduce the advantages of Firehawk®. Participants can also learn about the main features of the world's only Target Eluting Stent through watching videos.
 
"We have spent eight years on research and development to make Firehawk® the lowest drug dosage DES in the world," said Qiyi Luo, Chief Technology Officer of MicroPort Scientific Corporation. "After launched in China, Firehawk® has helped in improving life quality of many Chinese patients. We hope to take this opportunity of TCT to bring this revolutionary product to the international market to help more patients around the world."